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We have generated eight mAbs (MW1–8) that bind the epitopes
polyglutamine (polyQ), polyproline (polyP), or the C terminus of
exon 1 in huntingtin (htt) protein. In the brains of Huntington’s
disease (HD) mouse models, the anti-polyQ mAbs bind to various
cytoplasmic compartments, whereas the anti-polyP and anti-C
terminus mAbs bind nuclear inclusions containing htt. To use these
mAbs as intracellular perturbation agents, we have cloned and
expressed the antigen-binding domains of three of the mAbs as
single-chain variable region fragment Abs (scFvs). In 293 cells
cotransfected with htt exon 1 containing an expanded polyQ
domain, MW1, MW2, and MW7 scFvs colocalize with htt exon 1.
Moreover, these scFvs coimmunoprecipitate with htt exon 1 in cell
extracts. In perturbation experiments, MW7 scFv, recognizing the
polyP domains of htt, significantly inhibits aggregation as well as
the cell death induced by mutant htt protein. In contrast, MW1 and
MW2 scFvs, recognizing the polyQ stretch, stimulate htt aggrega-
tion and apoptosis. Therefore, these anti-htt scFvs can be used to
investigate the role of the polyP and polyQ domains in HD patho-
genesis, and antibody binding to the polyP domain has potential
therapeutic value in HD.
Huntington’s disease (HD), a fatal neurodegenerative disor-der, is caused by abnormal expansion of CAG repeats that
translate into an extended polyglutamine (polyQ) stretch in exon
1 of the protein huntingtin (htt) (1). Mutant htt with 40 CAG
repeats gains a toxic function and induces death in subpopula-
tions of neurons in the striatum and cortex (2–4). A hallmark of
HD and other polyQ diseases is the formation of insoluble
protein aggregates in affected neurons (5, 6). A major compo-
nent of the aggregates in HD is the N terminus exon 1 of mutant
htt (2, 5–8). Abnormal behavior and aggregate formation are
also seen in transgenic mice expressing htt exon 1 with an
expanded polyQ stretch (9–11).
Neuronal death in HD has been variously attributed to polyQ
toxicity, activation of caspases, interference with transcriptional
machinery, and sequestrationinactivation of wild-type htt and
other important cellular factors (12–17). Several proteins that
interact with exon 1 of htt have been identified (14, 18–23), and
although the function of these proteins in the etiology of HD is
unclear, the transcriptional coactivator CREB-binding protein
(CBP) as well as proteins with WW domains have been impli-
cated in the HD pathology (18–21). Binding of htt to CBP has
been shown to repress CBP-mediated gene expression (18, 19).
Moreover, ectopic expression of CBP appears to block htt-
mediated toxicity, indicating that transcriptional dysregulation
may contribute to HD pathogenesis (19, 24). Several different
WW-containing proteins have been shown to interact with
proline-rich domains in the C terminus of htt exon 1 (20, 21).
These interactors include spliceosomes (HYPA and HYPC) and
transcription factors (HYPB), which appear to have a higher
affinity for expanded polyQ htt (20). By using specific antibody
reagents, these WW domain proteins have been detected in
postmortem brain sections associated with toxic htt N-terminal
fragments (21). Such aberrant interactions may play a role in the
pathology of HD.
Molecules that block the toxic effects of htt itself or the lethal
consequences of its binding to other proteins may provide clues
about HD pathogenesis and may also have potential as thera-
peutics. Intracellular expression of recombinant Abs is an ap-
proach to block the toxic effects of mutated proteins or other
pathogenic agents with high selectivity (25). In fact, intracellular
expression of an Ab against the N terminus of htt was shown to
inhibit aggregate formation induced in cultured cells by mutant
htt, although quantitative results on inhibiting htt toxicity were
not reported (26). We have generated eight mAbs (MW1–8) that
recognize polyQ, polyproline (polyP), or a unique epitope near
the C terminus of htt exon 1 (27). Here we report that intracel-
lular expression of some of these mAbs as recombinant, single-
chain variable region fragments (scFvs) targeted to different
regions of htt exon 1 can either block or enhance aggregation as
well as the cell death induced by a mutant htt.
Materials and Methods
Molecular Cloning of Antigen-Binding Domains of MW1–8. Total
RNA was extracted from hybridoma cell lines secreting each of
the anti-htt MW mAbs, and mRNA was purified by using
oligo-dT columns (Qiagen, Valencia, CA). Complementary
cDNA was produced for each mRNA pool by using random
hexanucleotide primers. The cDNAs served as sources of DNA
to amplify both variable region heavy (VH) and variable region
light (VL) chains for each mAb by using primers complementary
to the consensus sequences flanking each domain (Amersham
Pharmacia) and PCR technology. To generate recombinant
single-chain fragment Abs, the amplified VH and VL of each
mAb were linked by a 45-mer nucleotide encoding Gly-Ser.
These scFv genes were cloned into the M13 phagemid,
pCANTBE5 (Amersham Pharmacia), and used to transform
Escherichia coli, strain TG15, which supports production of
recombinant phage. The amplified recombinant phage popula-
tion was selected for binding on immunoblots to htt exon-1-
glutathione S-transferase (GST)-containing a 67-polyQ repeat.
Phage that specifically bound htt were eluted and used to reinfect
TG15 E. coli. Individual clones were tested again for htt binding,
and the nucleotide sequence of positive clones was determined
by the dideoxynucleotide chain-termination method.
Cultured Cells. 293 cells were grown in DMEM supplemented with
10% heat inactivated bovine serum, 2 mM glutamine, 1 mM
streptomycin and 100 international units of penicillin. Cells were
grown in 6-well plates to70% confluence and transfected with
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a total of 2 g of DNA by using lipofectamine, following the
manufacturer’s recommendations (Invitrogen).
Expression and Evaluation of scFvs. The reading frame for each scFv
was subcloned into the mammalian plasmid pcDNA3.1 in frame
with the Flag epitope for ease of detection (28). Selected clones
were amplified and used to transfect 293 cells, as described
above. Expression of scFvs was examined by Western blot
analysis of the transfected cell extracts, by using an anti-Flag Ab
(Sigma). For intracellular staining, transfected cells were fixed in
4% paraformaldehyde for 30 min at 4°C, permeabilized in 70%
methanol at 20°C for 1 h, and incubated with anti-Flag Ab
(1:1000) for 2 h. Cells expressing scFvs were detected by a goat
anti-mouse Ab conjugated to Alexa 594 (Molecular Probes), and
examined with a confocal microscope. To determine the effects
of scFvs on cell viability, 293 cells were cotransfected with each
scFv and a plasmid encoding enhanced green fluorescent protein
(EGFP; CLONTECH) to readily detect which cells were trans-
fected. Viable cells that expressed GFP were counted 4 days
after transfection by using a fluorescence microscope.
For colocalization experiments, scFvs and htt exon 1, contain-
ing a 103-Q domain fused to EGFP, obtained from the Cure
Huntington Disease Initiative Resource Bank (Univ. of Califor-
nia, Los Angeles; ref. 18), were cotransfected in 293 cells grown
on coverslips. At 24 h after transfection, cells were fixed, stained,
and examined as described. Depending on the experiment,
50–70% of the cells expressed EGFP. Coimmunoprecipitation
experiments were performed with 293 cell lysates cotransfected
as above. Briefly, cells were harvested 24 h after transfection and
lysed by sonication in buffer A (25 mM Hepes, pH 7.42.5 mM
MgCl250 mM NaCl1 mM EDTA1% Triton X-100). After
clearing the lysates by centrifugation at 14,300 rpm (Eppendorf
microcentrifuge) for 10 min at 4°C, 200 g of each lysate was
incubated at 4°C with rocking for 2 h with a 40-l slurry of
anti-Flag Ab coupled to protein A beads. The beads were then
washed five times in buffer A by using centrifugation at 5,000
rpm, and the complexes were resolved on SDSPAGE. For
Western blotting, rabbit anti-HD1-17 (ref. 8; Vivian Hook) and
anti-Flag (1:1000; Sigma) were used as the primary Abs. Sec-
ondary antibodies conjugated to horseradish peroxidase (HRP)
were used to detect the reactive protein bands by enhanced
chemiluminescence (Santa Cruz Biotechnology).
For aggregation studies, 293 cells cotransfected with mutant
htt exon 1 and an scFv were harvested 48 h after transfection.
Cells were lysed by sonication in buffer A. Lysates were centri-
fuged at 150,000  g in an SW55 rotor (Beckman Instruments,
Fullerton, CA) for 30 min (19). Pellets were dissolved in sample
buffer containing 2% SDS, boiled and analyzed by SDSPAGE,
and transferred to nitrocellulose membranes for Western blot-
ting. Aggregates were detected with anti-HD1–17 polyclonal
antibody as described.
Terminal Deoxynucleotidyltransferase-Mediated dUTP Nick End La-
beling (TUNEL) Assay. Two days after double transfection as above,
293 cells were fixed as described and washed three times in PBS.
The TUNEL reaction consisted of 25 units of terminal de-
oxynucleotidyltransferase and 1 mM dUTP conjugated to tet-
ramethylrhodamine (Roche Molecular Biochemicals) in 1
buffer2.5 mM CoCl2 in a final volume of 50 l (according to
manufacturer’s instructions). Coverslips with fixed cells were
laid over the reaction mixture and incubated at 37°C in a
humidified incubator. Samples were washed four times with PBS,
mounted on microscope slides, and examined by confocal mi-
croscopy. TUNEL-positive cells that were expressing mutant htt
exon 1 were counted from at least 16 independent microscope
fields with a 20 objective lens in four separate experiments.
The data were analyzed by using EXCEL software to determine
the standard deviation and the P value (t test).
Results
Cloning and Expression of Anti-htt scFvs. We previously generated
eight mAbs that bind the htt epitopes polyQ, polyP, or the C
terminus of exon 1 (27). Although MW1 stains htt in the
cytoplasm, MW2 displays vesicular staining of htt. Interestingly,
MW7 stains htt in the perinuclear region as well in the nuclear
inclusions formed by mutant htt (27). To examine the effects of
these mAbs on the biological activities of htt exon 1, we
generated scFvs for MW1 and MW2, which recognize the polyQ
domain, and MW7, which recognizes the polyP domains of htt
exon 1. The scFvs expressed in E. coli were tested for binding to
htt on immunoblots (data not shown), and positive clones were
selected for further characterization in mammalian cells.
To test for scFv expression, 293 cells were transfected with the
Flag-tagged scFvs and cell lysates were analyzed by Western
blotting. Full-length proteins for MW1, -2, and -7 scFvs were
detected by using an anti-Flag Ab (data not shown; see Fig. 2 A).
Histological examination of the transfected cells reveals that the
scFvs have a predominantly cytoplasmic distribution (Fig. 1).
Because other proteins besides htt contain polyQ and polyP
domains, it was of interest to test whether expression of the scFvs
has an effect on cell viability. The 293 cells were transfected with
scFvs along with a plasmid encoding EGFP as a transfection
marker for evaluating cell viability (19). After 4 days of growth,
the mean cell counts from at least 30 microscope fields in six
wells each revealed no significant differences between the
control (112 6), and the scFvs for MW1 (97 3), MW2 (117
4), and MW7 (113  5). Thus, by this measure, scFv expression
does not affect cell growth or viability.
SCFVs Bind htt in Living Cells. We used biochemical and histological
methods to determine whether the scFvs interact with htt in
living cells. Flag-tagged scFvs were coexpressed in 293 cells with
htt exon 1 containing a polyQ domain of 103 repeats, fused to
EGFP. The scFvs in Triton X-100 cell extracts were precipitated
with anti-Flag Ab and analyzed for the presence of htt exon 1 by
Western blotting. Similar amounts of each scFv were precipi-
Fig. 1. Anti-htt scFvs are localized in the cytoplasm and have no obvious
cytotoxic effects. The 293 cells were transfected with MW1, MW2, MW7 scFvs
or an empty scFv vector (c). Two days after transfection, cells were fixed and
stained with an anti-Flag antibody. The disposition of the scFvs and the
appearance of the cells is very similar in each condition.









tated with the anti-Flag Ab (Fig. 2A; 33-kDa bands). Staining of
the same membrane with an Ab to the N-terminal 17 aa of htt
demonstrates that htt exon 1 coimmunoprecipitates with each
scFv (Fig. 2B; 86-kDa bands). Similar results were obtained
when htt exon 1 with a 25-Q stretch was used for transfection
(data not shown). Expression of Flag-tagged IB was used as
a negative control. Although IB was precipitated from the
extract by the anti-Flag Ab (Fig. 2 A; 44-kDa band), htt is not
coprecipitated (Fig. 2B). The bands below 30 kDa in Fig. 2B
likely represent nonspecific staining of the precipitating Ab.
To confirm binding of the scFvs to htt and to localize the sites
of interaction within cells, we used confocal microscopy to
examine 293 cells cotransfected with 103 polyQ htt and each
scFv. Although the scFvs are distributed throughout the cyto-
plasm in the absence of htt (Fig. 1), they are heavily concentrated
in the perinuclear region in the presence of htt exon 1, and
considerable colocalization is apparent (Fig. 3). These data
indicate that anti-htt scFvs bind mutant htt in living cells.
SCFVs Perturb htt-Induced Cell Death. To evaluate the effect of
scFvs on the toxic effects of mutant htt, we examined TUNEL
staining of 293 cells cotransfected with 103-Q htt-EGFP and
each scFv. Cells expressing mutant htt EGFP along with an
empty scFv vector display significant TUNEL staining, and
apoptotic bodies are observed starting about 12 h after trans-
fection (Fig. 4, control column). Surprisingly, TUNEL staining
is even more dramatic in the presence of MW1 or MW2 scFv and
mutant htt (Fig. 4). Thus, scFv binding to the polyQ domain
appears to accentuate the toxicity of mutant htt. In striking
contrast, expression of MW7 scFv inhibits the toxicity of mutant
htt (Fig. 4). These experiments were done under the same
conditions as in Fig. 2 A, which demonstrated equivalent expres-
sion of MW1, -2, and -7 scFvs in the cells.
To quantify the effects of scFv expression on mutant htt
toxicity, we counted TUNEL cells. The increase in mutant
htt-induced TUNEL staining in the presence of MW1 and -2
scFvs is 38% and 67%, respectively (P  0.05) (Fig. 5). In
contrast, the number of TUNEL cells in the presence of MW7
scFv is reduced to 33% of the control (P 0.05). Thus, although
the anti-polyQ mAbs MW1 and -2 accentuate the toxicity of
mutant htt, expression of the anti-polyP mAb MW7 inhibits the
toxicity of mutant htt.
MW7 scFv Reduces Aggregation of Mutant htt. Given that the role
of htt aggregation in HD is controversial, it was of interest to
evaluate the effects of scFv expression on mutant htt aggregation
in 293 cells. Aggregation was evaluated biochemically by exam-
ining the amount of htt that is precipitated from cell lysates by
centrifugation at 150,000  g for 30 min. The pellets contain
aggregated htt (or htt that is bound to large structures) that can
be solubilized by SDS treatment (Fig. 6A, 80-kDa bands), as well
as htt that remains insoluble after boiling in SDS and cannot
enter the gel (Fig. 6A, top of gel). Both such species of pelleted
htt are detected in extracts of cells transfected with mutant htt
exon 1 alone (Fig. 6A). Aggregation appears to be somewhat
stronger when mutant htt exon 1 is coexpressed with MW1 or
MW2 scFv. On the other hand, very little aggregated htt is found
in the presence of MW7 scFv. Scanning the bands at the top of
the gel yields values in arbitrary units of 68.8 for MW1, 54.3 for
MW2, 0.2 for MW7, and 48.8 for no scFv. Thus, coexpression of
MW7 scFv interferes with aggregation of mutant htt exon 1, and
there is a qualitative correlation between the effects of the scFvs
on htt aggregation and its toxicity. The expression of MW7 does
not appear to cause a depletion in the level of soluble htt,
however, as can be seen in Fig. 6B.
Discussion
We have cloned and expressed three recombinant antibodies
targeted to either the polyQ or polyP motifs of htt. As deter-
Fig. 2. The scFvs immunoprecipitate htt exon 1. The 293 cells were cotrans-
fected with htt exon 1-EGFP, either 25-residue polyQ (PQ25) or 103-residue
polyQ (PQ103), and a Flag-scFv or Flag-IB. (A) An anti-Flag antibody was
used to precipitate the expressed scFv proteins from lysates and for visualizing
them on Western blots. The MW scFv proteins migrate with an apparent
molecular mass of35 kDa, whereas the control IBmigrates as43 kDa. (B)
The same membranes were then stripped and reprobed with an anti-htt
antibody to detect the presence of htt of80 kDa (PQ103) or 50 kDa (PQ25).
Precipitation of the MW scFvs results in coprecipitation of either normal or
expanded-repeat htt, whereas precipitation of IB yields very little htt
coprecipitation.
Fig. 3. Anti-htt scFvs colocalize with htt. The 293 cells were cotransfected
with mutant htt and an scFv. Twenty-four hours later, cells were fixed and
stained with anti-Flag antibody (red), and htt was visualized by the fluores-
cence associated with its EGFP tag (green). Nuclei were visualized by a DNA
stain (blue). In each case, scFvs colocalize with htt.
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mined by coimmunoprecipitation and histological colocaliza-
tion, all three of scFvs bind htt in cells. In a functional pertur-
bation study, MW7, recognizing the polyP domains of htt,
inhibits cell death induced by mutant htt. Biochemical assays
show that WM7 coexpression also strongly inhibits htt aggrega-
tion. A recent study of this type showed that intracellular
expression of a mAb against the N terminus of htt also inhibits
aggregate formation induced in cultured cells by mutant htt exon
1 (26). The latter paper did not, however, report the effects of
this scFv on cell survival, and the connection between aggregates
and toxicity remains controversial. It is therefore important, if
surprising, that both MW1 and MW2, specific for the polyQ
domain, accelerate the cell death as well as the aggregate
formation induced in cultured cells by mutant htt. Because
overexpression of a polyQ stretch itself is toxic (29), it might have
been expected that blocking this domain in htt would lessen its
toxicity. Moreover, it has been hypothesized that aggregation
of htt involves stacking of -sheets of polyQ, forming polar
zippers (30). Therefore, molecules that bind to the polyQ
domain should block the stacking of htt and therefore inhibit
aggregate formation.
An alternative view is that the polyQ domain in htt is not
directly toxic; rather, the extended polyQ stretch alters the
binding of htt to other cell proteins, either positively or nega-
tively, and this altered interaction(s) is toxic. It is also possible
that the extended polyQ stretch results in the inhibition of htt
degradation (31), which could cause toxicity. This scenario has
not been observed in cultured lymphoblasts from HD patients,
however (32). In these latter two scenarios, intracellular Abs that
bind the extended polyQ domain could stabilize the mutant htt
conformation, thereby increasing its toxicity (and its aggrega-
tion). In this regard, it will be of interest to determine the effect
of MW1 and -2 scFv expression on the binding of htt to its known
partners, such as CBP, which is a complex that enhances cell
death (18, 19).
The inhibition of htt-induced cell death by MW7 targeted to
polyP domains raises a number of questions. Such domains are
Fig. 4. MW7 inhibits htt-induced cell death. The 293 cells were transfected with htt exon 1-EGFP plus empty vector or one of the anti-htt scFvs. The transfected
cells are visualized by GFP fluorescence (green), and dying cells by TUNEL staining (red). The presence of MW7 scFv decreases the number of TUNEL cells.
Fig. 5. MW7 inhibits htt-induced cell death whereas MW1 and -2 exacerbate
it. Cultures such as those shown in Fig. 4 were used to count TUNEL cells. All
three of the scFvs perturb the effect of htt toxicity, but only MW7 inhibits it.









binding sites for proteins with WW motifs (33). A potential
mechanism contributing to HD pathogenesis is the recruitment
of WW-rich proteins. In fact, several WW-containing proteins,
including CA150, spliceosomes, and transcription factors, can
interact with htt exon 1 (20–22). Moreover, interaction of some
of the WW proteins with htt exon 1 is enhanced in htt with an
expanded polyQ stretch (20, 21). Interestingly, the MW7 mAb
selectively stains intranuclear aggregates formed in the trans-
genic mouse model (27). This finding implies that expanded
polyQ makes the proline-rich motifs more available to binding to
WW-containing proteins or to MW7. Intracellular expression of
MW7 may therefore compete with the pernicious recruitment of
other proteins that leads to cell death. It is also possible that
binding of MW7 scFv to mutant htt may impose a conformation
that enhances proteosome-mediated degradation.
We quantified htt aggregation by using a biochemical rather
than a morphological method. The latter proved somewhat
unreliable, as large aggregates containing htt were sometimes
lost from the dishes during histological processing. It is notable
that true nuclear aggregates of htt are not usually seen in this cell
system (1% of the cells have clearly visible EGFP-labeled
aggregates in the nucleus). A similar observation has been made
for other tagged htt constructs expressed in 293 cells (18, 26, 34,
35) and in PC12 cells (E. Schweitzer, personal communication).
One explanation for this observation is that the rapid cell death
caused by the expanded repeat construct does not allow time for
aggregates to form in the nucleus, yielding instead the large
aggregates seen in Fig. 2. It is also possible that fusion of htt with
GFP interferes with its nuclear aggregation. Biochemical anal-
ysis clearly shows, however, that mutant htt does aggregate in
these cells and that expression of MW7 scFv strikingly reduces
this aggregation. This result does not appear to be caused by
lowering the concentration of soluble mutant htt in the cell, as
this is not appreciably affected by MW7 expression. Alterna-
tively, MW7 may stabilize mutant htt in a conformation that is
less amenable to stacking by means of the polyQ stretch. It is
striking that in transgenic mouse brain, the MW7 mAb strongly
stains htt aggregates formed by mutant protein in the nucleus, as
well as the perinuclear region, whereas it stains very little of
normal htt and mutant htt found in various cytoplasmic locations
(27). If such histological data apply to events in the living cell,
it would argue that the MW7 scFv does not bind to mutant htt
until it is in aggregates in the perinuclear region. This implies
that MW7 scFv may act, not by inhibiting the formation of
aggregates, but rather by enhancing their turnover.
In considering MW7 scFv as a potential therapeutic agent, a
key question is whether its expression would disrupt the function
of other polyP-containing proteins in the cell. We observed no
deleterious effects on normal 293 cells 4 days after transfection
with MW7 scFv. A more detailed analysis of cell physiology
would be required for firm conclusions, however. The most
important experiments regarding side effects of this potential
therapeutic agent will need to be done in animal models.
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